Pharmacological Therapy of Obesity: Past, Present, and Future
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
There is probably no medical condition for which a safe and effective form of pharmacotherapy is more highly desired than obesity. Neither is there a condition for which effective treatment would spare so much suffering for so many individuals. There is abundant evidence from epidemiological and interventional studies to suggest that morbidity from diabetes, cardiovascular disease, cerebrovascular disease, osteoarthritis, sleep apnea, and certain cancers could all be reduced in proportion to a reduction in body fat content. Past forms of pharmacotherapy for obesity have often been misguided, and currently available drugs are less effective than we would like them to be. However, our growing understanding of peripheral signals and central nervous system (CNS) pathways involved in the regulation of adiposity makes it very likely that effective new drugs will become available to treat obesity in the near future. This review will provide a brief history of obesity pharmacotherapy, discuss the status of currently available obesity drugs, and outline the major physiological pathways that will form the targets for future drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Central nervous system control of food intake
Schwartz, M. W., Woods, S. C., Porte, D., Seeley, R. J., & Baskin, D. G. (2000) · Nature · doi:10.1038/35007534 · Cited by 6,451
A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans
Cummings, D. E., Purnell, J. Q., Frayo, R. S., Schmidova, K., Wisse, B. E., & Weigle, D. S. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1714 · Cited by 2,940
Self-citationAntipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction
Clément, K., Vaisse, C., Lahlou, N., Cabrol, S., Pelloux, V., Cassuto, D., Gourmelen, M., Dina, C., Chambaz, J., Lacorte, J.-M., et al. (1998) · Nature · doi:10.1038/32911 · Cited by 2,346
Effects of Recombinant Leptin Therapy in a Child with Congenital Leptin Deficiency
Farooqi, I. S., Jebb, S. A., Langmack, G., Lawrence, E., Cheetham, C. H., Prentice, A. M., Hughes, I. A., McCamish, M. A., & O'Rahilly, S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909163411204 · Cited by 1,998
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Sniffing neuropeptides: A transnasal approach to the human brain
Born, J., Lange, T., Kern, W., McGregor, G. P., Bickel, U., & Fehm, H. L. (2002) · Nature Neuroscience · doi:10.1038/nn0602-849 · Cited by 1,356
Appetite-suppressant drugs and the risk of primary pulmonary hypertension
Abenhaim, L., Moride, Y., Brenot, F., Rich, S., Benichou, J., Kurz, X., Higenbottam, T., Oakley, C., Wouters, E., Aubier, M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350901 · Cited by 1,162
Jackson, R. S., Creemers, J. W. M., Ohagi, S., Raffin-Sanson, M.-L., Sanders, L., Montague, C. T., Hutton, J. C., & O'Rahilly, S. (1997) · Nature Genetics · doi:10.1038/ng0797-303 · Cited by 1,153
Haller, C. A., & Benowitz, N. L. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012213432502 · Cited by 956
Cited by
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
Pancreatic lipase inhibitors from natural sources: Unexplored potential
Birari, R. B., & Bhutani, K. K. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.07.024 · Cited by 871
Neurogenesis in the Hypothalamus of Adult Mice: Potential Role in Energy Balance
Kokoeva, M. V., Yin, H., & Flier, J. S. (2005) · Science · doi:10.1126/science.1115360 · Cited by 702
Possible anti-obesity therapeutics from nature--a review
Yun, J. W. (2010) · Phytochemistry · doi:10.1016/j.phytochem.2010.07.011 · Cited by 619
Noeman, S. A., Hamooda, H. E., & Baalash, A. A. (2011) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-3-17 · Cited by 518
Natural products to drugs: natural product derived compounds in clinical trials
Butler, M. S. (2005) · Natural Product Reports · doi:10.1039/b402985m · Cited by 491
A review of psychosocial pre‐treatment predictors of weight control
Teixeira, P. J., Going, S. B., Sardinha, L. B., & Lohman, T. G. (2005) · Obesity Reviews · doi:10.1111/j.1467-789x.2005.00166.x · Cited by 449
“Low-carbohydrate diets (19), meal replacement plans (164), exercise-only (20) and nondieting approaches (165) are available, as are self-help (166), Internet- (167) and doctor-delivered modalities (168,169), individual, psychologically intense programmes (170), short-term interventions (171), long-term care (172) and…”
BackgroundObesity and hypertension: two epidemics or one?
Davy, K. P., & Hall, J. E. (2004) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00707.2003 · Cited by 280
Shin, S., Wakabayashi, J., Yates, M. S., Wakabayashi, N., Dolan, P. M., Aja, S., Liby, K. T., Sporn, M. B., Yamamoto, M., & Kensler, T. W. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.08.022 · Cited by 275
Bryzgalova, G., Effendic, S., Khan, A., Rehnmark, S., Barbounis, P., Boulet, J., Dong, G., Singh, R., Shapses, S., Malm, J., et al. (2008) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2008.06.010 · Cited by 94
Schwartz, M. W., & Niswender, K. D. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0906 · Cited by 93
Epidemiology of Obesity and Pharmacologic Treatment Options
Shettar, V., Patel, S., & Kidambi, S. (2017) · Nutrition in Clinical Practice · doi:10.1177/0884533617713189 · Cited by 26
“This class of drugs was among the earliest category of medications that were introduced for weight loss with amphetamines in 1938.(44) These drugs reduce hunger sensation overall and can help reduce weight.”
Background
Metadata
- Authors
- Weigle, D. S.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2003-06
- Volume
- 88
- Issue
- 6
- Pages
- 2462-2469
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2171611607
- Cited by
- 148
- References
- 19
- FWCI
- 5.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.